Advances in adjuvant therapy of biliary tract cancer: an overview of current clinical evidence based on phase II and III trials

A Belkouz; J W Wilmink; N Haj Mohammad; J Hagendoorn; J de Vos-Geelen; C H C Dejong; M Y V Homs; B Groot Koerkamp; T M van Gulik; M G H van Oijen; C J A Punt; H Klümpen

doi:10.1016/j.critrevonc.2020.102975

Advances in adjuvant therapy of biliary tract cancer: an overview of current clinical evidence based on phase II and III trials

A Belkouz, J W Wilmink, N Haj Mohammad, J Hagendoorn, J de Vos-Geelen, C H C Dejong, M Y V Homs, B Groot Koerkamp, T M van Gulik, M G H van Oijen, C J A Punt, H Klümpen

Research output: Contribution to journal › Review article › peer-review

6 Downloads (Pure)

Abstract

Patients with biliary tract cancer (BTC) have a high recurrence rate after complete surgical resection. To reduce the risk of recurrence and to improve survival, several chemotherapeutic agents that have shown to be active in locally advanced and metastatic BTC have been investigated in the adjuvant setting in prospective clinical trials. Based on the results of the BILCAP phase III trial, capecitabine was adapted as the standard of care by the ASCO clinical practice guideline. Ongoing randomized controlled trials mainly compare capecitabine with gemcitabine-based chemotherapy or chemoradiotherapy. This review provides an update of adjuvant therapy in BTC based on published data of phase II and III trials and ongoing randomized controlled trials (RCTs).

Original language	English
Article number	102975
Number of pages	9
Journal	Critical Reviews in Oncology/Hematology
Volume	151
Early online date	27 Apr 2020
DOIs	https://doi.org/10.1016/j.critrevonc.2020.102975
Publication status	Published - Jul 2020

Keywords

Adjuvant therapy
Biliary tract cancer
Chemoradiotherapy
Chemotherapy
Cholangiocarcinoma
Neoadjuvant therapy

Access to Document

10.1016/j.critrevonc.2020.102975

1-s2.0-S104084282030113X-mainFinal published version, 477 KBLicence: CC BY

Cite this

Belkouz, A., Wilmink, J. W., Haj Mohammad, N., Hagendoorn, J., de Vos-Geelen, J., Dejong, C. H. C., Homs, M. Y. V., Groot Koerkamp, B., van Gulik, T. M., van Oijen, M. G. H., Punt, C. J. A., & Klümpen, H. (2020). Advances in adjuvant therapy of biliary tract cancer: an overview of current clinical evidence based on phase II and III trials. Critical Reviews in Oncology/Hematology, 151, Article 102975. https://doi.org/10.1016/j.critrevonc.2020.102975

@article{0462ca89253c4896a49710d7e19bac8b,

title = "Advances in adjuvant therapy of biliary tract cancer: an overview of current clinical evidence based on phase II and III trials",

abstract = "Patients with biliary tract cancer (BTC) have a high recurrence rate after complete surgical resection. To reduce the risk of recurrence and to improve survival, several chemotherapeutic agents that have shown to be active in locally advanced and metastatic BTC have been investigated in the adjuvant setting in prospective clinical trials. Based on the results of the BILCAP phase III trial, capecitabine was adapted as the standard of care by the ASCO clinical practice guideline. Ongoing randomized controlled trials mainly compare capecitabine with gemcitabine-based chemotherapy or chemoradiotherapy. This review provides an update of adjuvant therapy in BTC based on published data of phase II and III trials and ongoing randomized controlled trials (RCTs).",

keywords = "Adjuvant therapy, Biliary tract cancer, Chemoradiotherapy, Chemotherapy, Cholangiocarcinoma, Neoadjuvant therapy",

author = "A Belkouz and Wilmink, {J W} and {Haj Mohammad}, N and J Hagendoorn and {de Vos-Geelen}, J and Dejong, {C H C} and Homs, {M Y V} and {Groot Koerkamp}, B and {van Gulik}, {T M} and {van Oijen}, {M G H} and Punt, {C J A} and H Kl{\"u}mpen",

note = "Funding Information: A brief version of this review has been published in the Dutch Journal of Oncology (NTvO). (Link: https://www.ariez.nl/wp-content/uploads/2019/02/NTVO1-2019_art.Belkouz.pdf). We received written permission to use parts of this article in the current manuscript. This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors. Study concept and design: A. Belkouz, C.J.A. Punt, and H. Kl?mpen. Interpretation of data: all authors. Drafting of the manuscript: A. Belkouz. Critical revision of the manuscript for important intellectual content: all authors. Study supervision: C.J.A. Punt and H. Kl?mpen. Publisher Copyright: {\textcopyright} 2020 The Author(s) Copyright: Copyright 2020 Elsevier B.V., All rights reserved.",

year = "2020",

month = jul,

doi = "10.1016/j.critrevonc.2020.102975",

language = "English",

volume = "151",

journal = "Critical Reviews in Oncology/Hematology",

issn = "1040-8428",

publisher = "Elsevier Ireland Ltd",

}

Belkouz, A, Wilmink, JW, Haj Mohammad, N , Hagendoorn, J, de Vos-Geelen, J, Dejong, CHC, Homs, MYV, Groot Koerkamp, B, van Gulik, TM, van Oijen, MGH, Punt, CJA & Klümpen, H 2020, 'Advances in adjuvant therapy of biliary tract cancer: an overview of current clinical evidence based on phase II and III trials', Critical Reviews in Oncology/Hematology, vol. 151, 102975. https://doi.org/10.1016/j.critrevonc.2020.102975

TY - JOUR

T1 - Advances in adjuvant therapy of biliary tract cancer

T2 - an overview of current clinical evidence based on phase II and III trials

AU - Belkouz, A

AU - Wilmink, J W

AU - Haj Mohammad, N

AU - Hagendoorn, J

AU - de Vos-Geelen, J

AU - Dejong, C H C

AU - Homs, M Y V

AU - Groot Koerkamp, B

AU - van Gulik, T M

AU - van Oijen, M G H

AU - Punt, C J A

AU - Klümpen, H

N1 - Funding Information: A brief version of this review has been published in the Dutch Journal of Oncology (NTvO). (Link: https://www.ariez.nl/wp-content/uploads/2019/02/NTVO1-2019_art.Belkouz.pdf). We received written permission to use parts of this article in the current manuscript. This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors. Study concept and design: A. Belkouz, C.J.A. Punt, and H. Kl?mpen. Interpretation of data: all authors. Drafting of the manuscript: A. Belkouz. Critical revision of the manuscript for important intellectual content: all authors. Study supervision: C.J.A. Punt and H. Kl?mpen. Publisher Copyright: © 2020 The Author(s) Copyright: Copyright 2020 Elsevier B.V., All rights reserved.

PY - 2020/7

Y1 - 2020/7

N2 - Patients with biliary tract cancer (BTC) have a high recurrence rate after complete surgical resection. To reduce the risk of recurrence and to improve survival, several chemotherapeutic agents that have shown to be active in locally advanced and metastatic BTC have been investigated in the adjuvant setting in prospective clinical trials. Based on the results of the BILCAP phase III trial, capecitabine was adapted as the standard of care by the ASCO clinical practice guideline. Ongoing randomized controlled trials mainly compare capecitabine with gemcitabine-based chemotherapy or chemoradiotherapy. This review provides an update of adjuvant therapy in BTC based on published data of phase II and III trials and ongoing randomized controlled trials (RCTs).

AB - Patients with biliary tract cancer (BTC) have a high recurrence rate after complete surgical resection. To reduce the risk of recurrence and to improve survival, several chemotherapeutic agents that have shown to be active in locally advanced and metastatic BTC have been investigated in the adjuvant setting in prospective clinical trials. Based on the results of the BILCAP phase III trial, capecitabine was adapted as the standard of care by the ASCO clinical practice guideline. Ongoing randomized controlled trials mainly compare capecitabine with gemcitabine-based chemotherapy or chemoradiotherapy. This review provides an update of adjuvant therapy in BTC based on published data of phase II and III trials and ongoing randomized controlled trials (RCTs).

KW - Adjuvant therapy

KW - Biliary tract cancer

KW - Chemoradiotherapy

KW - Chemotherapy

KW - Cholangiocarcinoma

KW - Neoadjuvant therapy

UR - http://www.scopus.com/inward/record.url?scp=85085195492&partnerID=8YFLogxK

U2 - 10.1016/j.critrevonc.2020.102975

DO - 10.1016/j.critrevonc.2020.102975

M3 - Review article

C2 - 32464483

SN - 1040-8428

VL - 151

JO - Critical Reviews in Oncology/Hematology

JF - Critical Reviews in Oncology/Hematology

M1 - 102975

ER -

Advances in adjuvant therapy of biliary tract cancer: an overview of current clinical evidence based on phase II and III trials

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this